Navigating Medicare's GLP-1 Discount: Lessons for Employer Health Plans

In July 2023, Medicare rolled out its GLP-1 Bridge program, a significant initiative intended to democratize access to weight-loss medications for seniors. With a monthly copay of only $50 for select GLP-1 drugs, the program promises to alleviate costs for many Medicare Part D enrollees. However, there’s a crucial caveat: this discount is unavailable to patients diagnosed with certain serious conditions. This exclusion raises important considerations for brokers and employers designing health plans that include GLP-1 medications, as the structure of coverage can drastically affect patient access and affordability.

The GLP-1 Bridge, managed by the Centers for Medicare and Medicaid Services (CMS), includes three medications: Wegovy, Zepbound (KwikPen formulation), and Foundayo. The demonstration project runs until December 31, 2027, and aims to collect data on whether improved access to these drugs can reduce overall Medicare costs. However, the program operates outside the traditional Part D framework, meaning that many patients who could benefit from these drugs due to their medical conditions are likely to face higher out-of-pocket expenses, ranging from $200 to $600 per month under standard Part D plans.

Understanding the GLP-1 Bridge Program

This innovative program is a response to a long-standing restriction in Medicare that prohibits coverage for drugs prescribed solely for weight loss. The Bridge cleverly circumvents this limitation by categorizing itself as a demonstration project. By doing so, it provides a unique opportunity for eligible enrollees, specifically those without existing conditions that qualify for GLP-1 treatment under standard Medicare rules. Unfortunately, those with diagnoses such as Type 2 diabetes, obstructive sleep apnea, or metabolic dysfunction-associated steatohepatitis must revert to their standard Part D plans, where costs can be prohibitive.

Eligibility and Cost Implications

According to recent estimates, approximately 3.8 million Medicare Part D enrollees qualify for the Bridge program based on 2023 claims data. However, this figure stands in stark contrast to the 9.7 million individuals who meet clinical criteria for obesity or overweight. The real issue arises when considering the 5.9 million patients with conditions that disqualify them from the Bridge discount, forcing them to navigate the more expensive landscape of Part D. Experts predict that if participation in the program reaches 25%, Medicare could incur costs of around $3.3 billion; if it hits 75%, this figure could soar to $10 billion.

The Challenge of Coverage Design for Employers

The structural gaps in the GLP-1 Bridge program offer valuable lessons for employers and brokers when designing pharmacy benefits. As the demand for GLP-1 medications increases, employers must consider how their plan structures can accommodate the diverse needs of their workforce. Notably, while the Bridge program is geared towards weight loss, the same drugs are also indicated for various other conditions, including diabetes and cardiovascular disease. This complexity necessitates a nuanced approach to coverage design.

Current Trends in Employer Coverage

• In a 2026 survey by the International Foundation of Employee Benefit Plans (IFEBP), 60% of employers reported covering GLP-1 drugs solely for diabetes.
• Only 36% of employers offered coverage for both diabetes and weight loss, indicating a potential gap in meeting employee needs.
• GLP-1 drugs accounted for 11.4% of annual claims among employers who cover them for weight loss, a significant increase from 6.9% in 2023.

This data reflects a growing trend where employers are increasingly tightening their policies instead of expanding coverage. The percentage of large employers that provide GLP-1 coverage for obesity has decreased from 72% in 2025 to 60% in 2026, suggesting a shift toward more restrictive utilization management practices rather than a comprehensive approach to employee health.

Impact on Patient Care and Affordability

The implications of these coverage decisions extend beyond mere statistics. They translate into real-world challenges for employees who may require GLP-1 medications to manage their health effectively. Dr. Taylor Lacy, a primary care physician, pointed out that the Bridge program unintentionally leaves behind the patients with the most significant medical needs. Even for those who qualify for Part D coverage, the financial burden remains heavy, with monthly copays often exceeding what many can afford. This disparity between coverage and affordability underscores the need for a more structured access framework in employer health plans.

Emerging Solutions for Employers

As employers navigate these complexities, many are turning to point-solution vendors for GLP-1 management. A recent survey indicated that 28% of employers now use these vendors, a notable increase from 11% in 2024. These solutions often bundle prior authorization processes, clinical eligibility assessments, and patient support services, creating a more streamlined approach to medication access. By adopting structured frameworks, employers can better manage the cost pressures associated with GLP-1 medications and ensure that employees receive the necessary treatments.

Key Takeaways

• The GLP-1 Bridge program offers a discounted path for some seniors but excludes those with serious health conditions.
• Employers face challenges in designing coverage that accommodates diverse medical needs associated with GLP-1 medications.
• Trends indicate a tightening of GLP-1 coverage among large employers, which may affect employee access to necessary treatments.
• Structured access frameworks and point-solution vendors can help employers navigate the complexities of GLP-1 coverage.

Frequently Asked Questions

What is the GLP-1 Bridge program?

The GLP-1 Bridge program is a Medicare initiative that allows eligible seniors to access certain weight-loss medications at a discounted rate of $50 per month. However, it excludes individuals with certain health conditions, such as diabetes or sleep apnea, who must instead utilize standard Medicare Part D plans, which typically have much higher copays.

Who qualifies for the GLP-1 Bridge program?

Eligibility for the GLP-1 Bridge program is primarily based on the absence of qualifying medical conditions that would necessitate coverage under standard Medicare Part D. In 2023, an estimated 3.8 million enrollees fit the criteria, but a significant number remain excluded due to other health issues.

How are employers responding to the changes in GLP-1 coverage?

Employers are increasingly tightening their policies regarding GLP-1 coverage. A recent survey indicated that while a majority cover these drugs for diabetes, fewer employers are offering broader coverage for weight loss. Many are turning to point-solution vendors to better manage costs and streamline access to GLP-1 medications.

What can brokers do to assist employers with GLP-1 coverage?

Brokers can play a crucial role by helping employers design pharmacy benefits that are responsive to the diverse needs of their employees. This includes developing structured access frameworks that account for various medical indications for GLP-1 medications, thereby improving patient access and affordability.